Roquefort Therapeutics (LON:ROQ) Stock Price Up 10.2% – Should You Buy?

Roquefort Therapeutics plc (LON:ROQ) was up 10.2% on Thursday . The company traded as high as GBX 5.50 ($0.07) and last traded at GBX 4.47 ($0.06). Approximately 1,300,436 shares changed hands during trading, an increase of 117% from the average daily volume of 599,877 shares. The stock had previously closed at GBX 4.05 ($0.05).

Roquefort Therapeutics Trading Down 0.5 %

The firm has a market capitalization of £5.40 million, a PE ratio of -418.00 and a beta of 0.05. The company has a quick ratio of 3.07, a current ratio of 0.79 and a debt-to-equity ratio of 12.37. The company’s 50-day simple moving average is GBX 4.33 and its 200 day simple moving average is GBX 4.14.

Roquefort Therapeutics Company Profile

Roquefort Therapeutics plc, a biotechnology company, engages in the development of medicines for the treatment of cancer. The company's pre-clinical development pipeline comprises Midkine antibodies with significance in vivo efficacy and toxicology studies; Midkine RNA therapeutics with novel anti-cancer gene editing action; Midkine mRNA therapeutics with novel anti-cancer approach; STAT-6 siRNA therapeutics targeting solid tumors with significance in vivo efficacy; and MK cell therapy with direct and NK-mediated anti-cancer action.